Tuesday, July 19, 2016

BRIEF-Cerulean Pharma receives FDA fast track designation for ovarian cancer treatment

* Receives FDA fast track designation for CRLX101 for the

treatment of platinum-resistant ovarian cancer

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)